In a multicenter study involving over 747,000 women who had mammography screening, those who paid for AI-enhanced screening had a 21 percent higher recall rate and a 15 percent higher positive predictive value (PPV) for breast cancer, according to research presented at the Radiological Society of North America (RSNA) conference.
Emerging multicenter research suggests that over one-third of women are willing to pay for artificial intelligence (AI)-enhanced mammography screening and had a 43 percent higher average cancer detection rate (CDR) than those who did not have adjunctive AI screening.
For the multicenter study, presented at the Radiological Society of North America (RSNA) conference, researchers reviewed mammography screening data from 747,604 women and compared the CDR, recall rate and positive predictive value (PPV) for women who opted to self-pay for AI-enhanced screening and those who did not.
At one year, the researchers found that women who had adjunctive AI screening had a 43 percent higher CDR (5.95 vs. 4.15 per 1000). The study authors noted that the use of adjunctive AI accounted for 21 percent of the increased CDR and maintained that 22 percent of the increased CDR was due to patients at higher risk for breast cancer enrolling more frequently for adjunctive AI screening.
In a multicenter study evaluating patient self-pay for the use of adjunctive AI in mammography screening, researchers found that adjunctive AI led to a 43 percent higher cancer detection rate, a 21 percent higher recall rate and a 15 percent higher positive predictive value in comparison to women who did not have adjunctive AI.
“These data indicate that many women are eager to utilize AI to enhance their screening mammogram, and when AI is coupled with a safeguard review, more cancers are found,” noted Gregory Sorensen, M.D., a senior author of the study and chief executive officer of DeepHealth.
The use of adjunctive AI yielded a 21 percent higher recall rate (10.9 percent vs. 8.8 percent) but also led to a 15 percent higher PPV (5.4 percent vs. 4.6 percent), according to the study authors.
(Editor’s note: For additional coverage from the RSNA conference, click here.)
“The AI-driven enhanced review program leverages AI in a novel workflow to ensure women with suspicious findings get expert level care that could help detect many more breast cancers early,” emphasized Bryan Haslam, Ph.D., a co-author of the study and chief product officer at DeepHealth. “The number of women electing for this program is now at 36% and growing, and the rate of cancer detection continues to be substantially higher for those women.”
Reference
1. Sorensen AG, Haslam B, Louis L, Holt JS, Storella JM. Patient self-pay for AI-driven enhanced review program in screening mammography: initial experience. Poster presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.